Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 43

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 8
Chunk 43
---
 of specific development milestones. This technology pertains to among other things, the use of vaccines for the treatment
or prevention of ovarian cancers which express the anti-Mullerian hormone receptor 2 protein containing an extracellular domain (“AMHR2-ED”).
In healthy tissue, this protein regulates growth and development of egg-containing follicles in the ovary. While expression of AMHR2-ED
naturally and markedly declines during menopause, this protein is expressed at high levels in the ovaries of postmenopausal women with
ovarian cancer. Researchers at Cleveland Clinic believe that a vaccine targeting AMHR2-ED could prevent the occurrence of ovarian cancer.

In
May 2021, Cleveland Clinic was granted acceptance for our ovarian cancer vaccine technology into the NCI’s PREVENT program. The
NCI is a part of the National Institutes of Health (“NIH”). The PREVENT program is a peer-reviewed agent development program
designed to support pre-clinical development of innovative interventions and biomarkers for cancer prevention and interception towards
clinical trials. The scientific and financial resources of the PREVENT program are being used for our ovarian cancer vaccine technology
to perform virtually all pre-clinical research and development, manufacturing and IND enabling studies. This work is being performed
at NCI facilities, by NCI scientific staff and with NCI financial resources and will require no material financial expenditures by the
Company, nor the payment of any future consideration by the Company to NCI.

In
May 2024, based on the positive clinical results to date in the development of our breast cancer vaccine, we entered into a Joint Development
and Option Agreement with Cleveland Clinic to collaborate in efforts to develop additional vaccines for the prevention or treatment of
cancers. Working with Cleveland Clinic researchers, we are focusing on the same novel scientific mechanism as in our breast and ovarian
cancer vaccines, and working to discover additional retired proteins that may be associated with other forms of cancer, specifically
high incidence malignancies in the lung, colon and prostate.

Over
the next several quarters, we expect the development of our therapeutics and vaccines to be the primary focus of the Company. As part
of our legacy operations, the Company remains engaged in limited patent licensing activities of its various patent portfolios. We do
not expect these activities to be a significant part of the Company’s ongoing operations nor do we expect these activities to require
material financial resources or attention of senior management.

Over
the past several years, our revenue was derived from